MOTS-C

No cited study has given MOTS-c to a person and reported the result, and FDA says it has not identified any human exposure data on drug products containing it, by any route. The human record is measurement only: researchers have tracked the body's own MOTS-c in blood and muscle and how it shifts with exercise, age and metabolic disease.

The interest comes from mice. In the 2015 paper that named the peptide, MOTS-c prevented diet-induced obesity and insulin resistance in mice fed a high-fat diet, and a week of treatment brought muscle insulin sensitivity in 12-month-old mice back to the level of 3-month-old animals. A 2021 follow-up reported better treadmill running in young mice and better grip strength, stride and walking in very old ones.

MOTS-c is not approved by the FDA, sits on neither FDA compounding category since its nominators withdrew it, and is named on the WADA Prohibited List.

MOTS-c is short for mitochondrial open reading frame of the 12S rRNA-c. It is a 16 amino acid peptide coded inside a gene in mitochondrial DNA, the small separate genome that mitochondria carry, rather than in the cell nucleus. Changhan Lee, Pinchas Cohen and colleagues described it in Cell Metabolism in 2015.

It belongs to a small group called mitochondrial-derived peptides. Humanin and six small humanin-like peptides, SHLP1 to SHLP6, come from the neighbouring 16S rRNA gene; MOTS-c is the one from 12S. The working idea behind the group is that mitochondria use these peptides to report their own condition to the rest of the cell and, through the blood, to distant tissues.

The Folate to AMPK Route

In the 2015 work, cells engineered to overproduce MOTS-c had less 5-methyl-tetrahydrofolate, the most abundant active form of folate, less methionine and more homocysteine. The peptide slowed the folate cycle and the purine-building pathway tethered to it, which raised levels of AICAR, an intermediate that switches on AMPK, the cell's main energy sensor. Treated cells showed more phosphorylated AMPK and more phosphorylated ACC, one of its targets. In high-fat-fed mice, MOTS-c raised AMPK activation and expression of the GLUT4 glucose transporter in skeletal muscle, and the authors named skeletal muscle as its primary target organ.

A Signal That Reaches the Nucleus

A 2023 review in the Journal of Translational Medicine summarises cell work in which MOTS-c, normally found outside the nucleus, moved into it as early as 30 minutes after glucose restriction, serum deprivation or oxidative stress, and moved back out within 24 hours. That shift depended on AMPK. Inside the nucleus it interacted with stress-response transcription factors including NRF2 and bound promoter regions of genes carrying antioxidant response elements.

The same review lists what is still unexplained: how MOTS-c mRNA leaves the mitochondria to be translated in the cytoplasm, and how the peptide picks which nuclear genes to regulate.

Exercise raising MOTS-c is not evidence for injecting it. The firmest human result is that the body's own MOTS-c climbs when 10 sedentary young men cycle hard. That shows exercise produces it. It does not show that adding the peptide from outside reproduces what exercise does, and no cited study has tested that in a person.

"Low in metabolic disease" does not survive the split. Pooled across studies, blood MOTS-c ran lower in type 2 diabetes and higher in obesity. The common story that metabolic disease depletes MOTS-c and it needs topping up fits only half of that data, and even the diabetes half is an association.

The lifespan result was a trend. Late-life treatment in old mice gave a 6.4 percent longer median lifespan that did not reach significance over the full survival curve. A longevity claim built on it rests on a number its own authors asked larger cohorts to confirm.

An analog is not the molecule. The one human dosing trial named in the cited reviews used a modified MOTS-c analog. Whatever that programme found belongs to the analog, not to unmodified MOTS-c sold as a research peptide.

Safety in people is unknown. FDA states it has not identified human exposure data for MOTS-c by any route and lacks information on whether it would cause harm if given to humans. It also notes that compounded versions may pose significant risk of immunogenicity, an immune reaction against the peptide, for certain routes, along with complexities in peptide-related impurities and characterisation of the active ingredient. Those concerns stay published on FDA's page after the nominators withdrew the substance.

What the evidence shows: in mice, MOTS-c changes how muscle handles glucose, blunts the effects of a high-fat diet on weight, insulin and liver fat, and improves physical measures in very old animals, through a folate and AMPK route mapped in cells. In people, the body makes it, a hard exercise session raises it, and its blood level differs between people with type 2 diabetes, people with obesity and older adults.

What the evidence does not show is anything about a person taking it: not insulin sensitivity, not fat loss, not endurance, not ageing. The gap is not a set of small trials waiting for replication. For the unmodified peptide, no human dosing study is cited at all.

The human result with the clearest direction is the exercise one: a single interval session raised muscle MOTS-c nearly twelvefold in sedentary young men. That is a fact about what exercise does to the body's own peptide, not proof that the peptide is why exercise works.

Not an approved drug. FDA has not approved any MOTS-c product for any use.

Not on either FDA compounding category. FDA, which spells it MOTs-C, held it in Category 2 until on or about 22 April 2026, when the nominators withdrew the nomination. FDA did not resolve its safety concerns, and they remain published. MOTS-c was reviewed for obesity and osteoporosis at the FDA Pharmacy Compounding Advisory Committee meeting of 23 and 24 July 2026. FDA has posted the agenda, roster, voting questions and its own slides, but no minutes, transcript or vote tally, so no outcome is known. A committee recommendation is not an FDA decision and would not change legal status; rulemaking on the full record does that.

Not permitted in tested sport. WADA names it under S4.4.1, among AMPK activators, as mitochondrial open reading frame of the 12S rRNA-c (MOTS-c), prohibited at all times, in and out of competition.

Not interchangeable with its analog. A modified MOTS-c analog entered a registered human trial. Results for an engineered analog, whatever they are, do not transfer to the unmodified peptide.

I find MOTS-c genuinely interesting, and I want to be exact about why. A gene inside the mitochondria makes a signalling peptide, muscle makes more of it during hard exercise, and a variant carried by up to one in ten people of East Asian ancestry tracks with diabetes risk in men. That is real human biology, and it is a better foundation than most compounds marketed alongside it.

What it does not have is a single cited study of a person taking it. Every outcome that makes it sound useful, from insulin sensitivity to old mice walking further, comes from mice, mostly from one research group. I would rather say that plainly than inflate the mouse work or wave it away.

The human finding I keep returning to is the 11.9-fold rise in muscle MOTS-c after one cycling session. It says more about what training does than about what a vial does.